diazoxide choline · Vykat XR
Small molecule
Evidence outlook
Approved: Prader-Willi Syndrome
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Development in Obesity stopped as a strategic decision by the sponsor. Development continues in another indication. Source
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT03440814 NCT03440814 · Prader-Willi Syndrome Run by former owner Soleno Therapeutics The trial randomized 127 participants to DCCR or placebo and masked participants, care providers, and investigators. Its primary clinical endpoint, change in the caregiver-completed HQ-CT score at Week 13, was not statistically significant (p=0.1983), although selected secondary measures showed statistically significant differences, so the evidence is limited rather than strong. Registry: NCT03440814 | 3 | Hyperphagia Questionnaire (HQ-CT) Change From Baseline at Visit 7 (Week 13) (Baseline to Visit 7 (Week 13)) 2020-05-01 | Hyperphagia Questionnaire (HQ-CT) Change From Baseline at Visit 7 (Week 13) (Baseline to Visit 7 (Week 13)): DCCR -5.94 score on a scale (Standard Error 0.879) vs Placebo for DCCR -4.27 score on a scale (Standard Error 1.145) | Partial signal | link ↗ |
View 1 more trial
NCT03714373 NCT03714373 · Prader-Willi Syndrome Run by former owner Soleno Therapeutics After a mean of 3.3 years of open-label treatment, 77 patients with Prader-Willi syndrome were randomized 1:1 to continue VYKAT XR or switch to placebo for 16 weeks, double-blind. The primary endpoint, change in the observer-reported HQ-CT hyperphagia score, worsened significantly more on placebo, which is the basis of the US approval. The randomized-withdrawal design enrolls patients who already tolerated and responded to the drug, which limits how far the result generalises to treatment-naive patients. Source: US label section 14. Registry: NCT03714373 | 3 | Assess the safety of DCCR by evaluating the incidence and severity of adverse events reported (Baseline to end of OLE (up to 4 years)); Change from RW Period Baseline in HQ-CT Total Score (RW Period Baseline to Week 16) 2023-08-17 | Primary endpoint (Study 2-RWP, 16-week double-blind randomized withdrawal, 77 patients): change in HQ-CT Total Score at Week 16. The US label reports statistically significant worsening of hyperphagia in the placebo group relative to the VYKAT XR group (label Table 5). | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (3)
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Prader-Willi Syndrome: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Diazoxide Choline (Vykat XR): this drug | Approved | Small molecule | KATP channel | Partial signal | NCT03714373: Primary endpoint (Study 2-RWP, 16-week double-blind randomized withdrawal, 77 patients): change in HQ-CT Total Score at Week 16. The US label reports statistically significant worsening of hyperphagia in the placebo group relative to the VYKAT XR group (label Table 5). NCT03440814: Hyperphagia Questionnaire (HQ-CT) Change From Baseline at Visit 7 (Week 13) (Baseline to Visit 7 (Week 13)): DCCR -5.94 score on a scale (Standard Error 0.879) vs Placebo for DCCR -4.27 score on a scale (Standard Error 1.145) missed | |
| ARD-101 | Phase 3 | Small molecule | Bitter taste receptor (gut) | Partial signal | No reviewed efficacy summary in this indication | |
| Pitolisant (Wakix) | Phase 3 | Small molecule | Histamine H3 receptor (antagonist / inverse agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| CSTI-500 | Phase 2 | Small molecule | Serotonin/norepinephrine/dopamine transporters (SERT/NET/DAT) | Weak signal | NCT05504395: Single 10mg oral dose of CSTI-500 capsule formulation in PWS patients at Vanderbilt: no severe adverse events; PK confirmed bioequivalence to prior formulation/healthy-volunteer data; led to Phase 2a advancement. | |
| Setmelanotide (Imcivree) | Phase 2 | Peptide | MC4R | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent